4-chloro-5-fluoro-2-(propionamide)benzoic acid | 1450618-81-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chloro-5-fluoro-2-(propionamide)benzoic acid
• 英文别名: 4-Chloro-5-fluoro-2-(propionamido)benzoic acid；4-chloro-5-fluoro-2-(propanoylamino)benzoic acid
• CAS: 1450618-81-1
• 化学式: C₁₀H₉ClFNO₃
• 分子量: 245.638
• InChiKey: NDBWXABZJZQZPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-chloro-5-fluoro-2-(propionamide)benzoic acid 在 吡啶 、 亚磷酸三苯酯 作用下， 反应 0.42h， 生成 7-chloro-2-ethyl-6-fluoro-3-phenethylquinazolin-4(3H)-one
  参考文献：
  名称：

  Quinazolin-4-one Derivatives as Selective Histone Deacetylase-6 Inhibitors for the Treatment of Alzheimer’s Disease

  摘要：

  Novel quinazolin-4-one derivatives containing a hydroxamic acid moiety were designed and synthesized. All compounds were subjected to histone deacetylase (HDAC) enzymatic assays to identify selective HDAC6 inhibitors with nanomolar IC50 values. (E)-3-(2-Ethyl-7-fluoro-4-oxo-3-phenethyl-3,4-dihydroquinazolin-6-yl)-N-hydroxyacrylamide, 4h, NHis the most potent HDAC6 inhibitor (IC50, 8 nM). In vitro, these compounds induced neurite outgrowth accompanied by growth-associated protein 43 expression, and they enhanced the synaptic activities of PC12 and SH-SY5Y neuronal cells without producing toxic or mitogenic effects. Several of the compounds dramatically increased nonhistone protein acetylation, specifically of g-tubulin. Some of the more potent HDAC6 inhibitors decreased zinc-mediated beta-amyloid aggregation in vitro. N-Hydroxy-3-(2-methyl-4-oxo-3-phenethyl-3,4-dihydroquinazolin-7-yl)-acrylarnide, 3f, the most promising drug candidate, selectively inhibits HDAC6 (IC50,29 nM), practically does not affect human ether-a-go-go-related membrane channel activity (IC50 >10 mu M) or cytochrome P450 activity (IC50 >63 mu M) in vitro, and significantly improves learning-based performances of mice with beta-amyloid-induced hippocampal lesions.

  DOI：

  10.1021/jm400564j
• 作为产物：
  描述：

  3-氯-4-氟苯胺 在 溴 、 palladium diacetate 、 溶剂黄146 、 三乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 33.5h， 生成 4-chloro-5-fluoro-2-(propionamide)benzoic acid
  参考文献：
  名称：

  HISTONE DEACETYLASES (HDACS) INHIBITORS

  摘要：

  揭示了组蛋白去乙酰化酶抑制剂（HDACIs）和包含其的组合物。还公开了通过抑制HDAC来获益的治疗疾病和病况的方法。

  公开号：

  US20130267542A1

文献信息

• Histone deacetylases (HDACs) inhibitors
  申请人：ANNJI PHARMACEUTICAL CO., LTD.

  公开号：US09155739B2

  公开（公告）日：2015-10-13

  Histone deacetylases inhibitors (HDACIs) and methods for treating cancer in a subject in need thereof are disclosed. The HDACIs comprise a compound of Formula X. or a pharmaceutically acceptable salt thereof. In one embodiment of the invention, R1 is ethyl; R2 is 2-phenylethyl; R3 is hydrogen; R4 is fluoro; R5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; and R6 is hydrogen, or a salt thereof. In another embodiment of the invention, R1 is ethyl; R2 is 2-phenylethyl; R3 is hydrogen; R4 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; R5 is chloro or fluoro; and R6 is hydrogen.

  本发明揭示了组蛋白去乙酰化酶抑制剂（HDACIs）及其治疗需要的患者的癌症的方法。HDACIs包括化合物X的一个衍生物或其药学上可接受的盐。在本发明的一个实施例中，R1为乙基；R2为2-苯乙基；R3为氢；R4为氟；R5为（2E）-3-N-羟基氨基-3-氧代丙烯基；R6为氢，或其盐。在本发明的另一个实施例中，R1为乙基；R2为2-苯乙基；R3为氢；R4为（2E）-3-N-羟基氨基-3-氧代丙烯基；R5为氯或氟；R6为氢。
• US9155739B2
  申请人：——

  公开号：US9155739B2

  公开（公告）日：2015-10-13
• US9387209B2
  申请人：——

  公开号：US9387209B2

  公开（公告）日：2016-07-12